|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petty WJ and Paz-Ares L: Emerging
strategies for the treatment of small cell lung cancer: A review.
JAMA Oncol. 9:419–429. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vokes NI, Pan K and Le X: Efficacy of
immunotherapy in oncogene-driven non-small-cell lung cancer. Ther
Adv Med Oncol. 15:175883592311614092023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zong Z, Wei Y, Ren J, Zhang L and Zhou F:
The intersection of COVID-19 and cancer: Signaling pathways and
treatment implications. Mol Cancer. 20:76–82. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsamakis K, Gavriatopoulou M, Schizas D,
Stravodimou A, Mougkou A, Tsiptsios D, Sioulas V, Spartalis E,
Sioulas AD, Tsamakis C, et al: Oncology during the COVID-19
pandemic: Challenges, dilemmas and the psychosocial impact on
cancer patients. Oncol Lett. 20:441–447. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bounassar-Filho JP, Boeckler-Troncoso L,
Cajigas-Gonzalez J and Zavala-Cerna MG: SARS-CoV-2 as an oncolytic
virus following reactivation of the immune system: A review. Int J
Mol Sci. 24:243–249. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meo C, Palma G, Bruzzese F, Budillon A,
Napoli C and de Nigris F: Spontaneous cancer remission after
COVID-19: Insights from the pandemic and their relevance for cancer
treatment. J Transl Med. 21:273–278. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rahimmanesh I, Shariati L, Dana N,
Esmaeili Y, Vaseghi G and Haghjooy Javanmard S: Cancer occurrence
as the upcoming complications of COVID-19. Front Mol Biosci.
8:8131752021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurlapski M, Romanowicz G, Taszner M and
Zaucha JM: SARS-CoV-2-induced remission of advanced classical
Hodgkin lymphoma. Pol Arch Intern Med. 13:132–139. 2022.
|
|
10
|
Sollini M, Gelardi F, Carlo-Stella C and
Chiti A: Complete remission of follicular lymphoma after SARS-CoV-2
infection: from the ‘flare phenomenon’ to the ‘abscopal effect’.
Eur J Nucl Med Mol Imaging. 48:2652–2654. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barkhordar M, Rostami FT, Yaghmaie M,
Abbaszadeh M, Chahardouli B and Mousavi SA: Spontaneous complete
remission of acute myeloid leukemia in the absence of
disease-modifying therapy following severe pulmonary involvement by
coronavirus infectious disease-19. Case Rep Hematol.
2022:26036072022.PubMed/NCBI
|
|
12
|
Bulbul H, Nazli HE, Olgun A, Togay A and
Kahraman DS: Spontaneous remission of chronic lymphocytic leukemia
in a patient with SARS-CoV2. Leuk Res Rep. 18:103–106.
2022.PubMed/NCBI
|
|
13
|
Ottaiano A, Scala S, D'Alterio C, Trotta
A, Bello A, Rea G, Picone C, Santorsola M, Petrillo A and Nasti G:
Unexpected tumor reduction in metastatic colorectal cancer patients
during SARS-Cov-2 infection. Ther Adv Med Oncol.
13:175883592110114552021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ottaiano A, Santorsola M, Circelli L,
Cascella M, Petrillo N, Perri F, Casillo M, Granata V, Ianniello M,
Izzo F, et al: Genetic landscape of colorectal cancer patients
manifesting tumor shrinkage during SARS-Cov-2 infection. Ther Adv
Med Oncol. 14:175883592211383882022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Buchler T, Fiser L, Benesova J, Jirickova
H and Votrubova J: Spontaneous regression of metastatic renal cell
carcinoma after SARS-CoV-2 infection: A report of two cases. Curr
Oncol. 28:3403–3407. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daly JL, Simonetti B, Klein K, Chen KE,
Williamson MK, Anton-Plagaro C, Shoemark DK, Simon-Gracia L, Bauer
M, Hollandi R, et al: Neuropilin-1 is a host factor for SARS-CoV-2
infection. Science. 370:861–865. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Challenor S and Tucker D:
SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol.
192:415–421. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasin F, Mascalchi Calveri M, Calabrese A,
Pizzarelli G, Bongiovanni I, Andreoli M, Cattaneo C and Rignanese
G: Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma.
Acta Biomed. 91:Aug 10–2020.(Epub ahead of print).
|
|
19
|
Lin D, Shen Y and Liang T: Oncolytic
virotherapy: Basic principles, recent advances and future
directions. Signal Transduct Target Ther. 8:156–173. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dock G: The influence of complicating
diseases upon leukemia. Am J Med Sci. 127:563–592. 1904. View Article : Google Scholar
|
|
21
|
Kristin DP and Greg MD: Integrating innate
and adaptive immunity in oncolytic virus therapy. Trends Cancer.
23:190–196. 2023.
|
|
22
|
Yun CO, Hong J and Yoon AR: Current
clinical landscape of oncolytic viruses as novel cancer
immunotherapeutic and recent preclinical advancements. Front
Immunol. 13:95–104. 2022. View Article : Google Scholar
|
|
23
|
Muscolini M, Tassone E and Hiscott J:
Oncolytic immunotherapy: Can't start a fire without a spark.
Cytokine Growth Factor Rev. 56:94–101. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hamad A, Yusubalieva GM, Baklaushev VP,
Chumakov PM and Lipatova AV: Recent developments in glioblastoma
therapy: Oncolytic viruses and emerging future strategies. Viruses.
15:106–119. 2023. View Article : Google Scholar
|
